GT Biopharma considers Phase 1b trial of GTB-5550 with KRAS inhibitor in pancreatic cancer
GTBP•GT Biopharma presented preclinical results showing GTB-5550 combined with a KRAS inhibitor improved pancreatic tumor control in animal models. The company is considering a Phase 1b study of the combination in pancreatic cancer patients.
1. Preclinical combination results
GT Biopharma presented results at SITC on November 6, 2026, showing that GTB-5550 combined with a KRAS inhibitor improved pancreatic tumor control in animal models. The combination cleared tumors in several animals, reduced local invasion and prevented metastasis.
2. Trial plans
A Phase 1a/1b trial of GTB-5550 monotherapy is enrolling patients across multiple tumor types, including pancreatic ductal adenocarcinoma. The company is considering a future Phase 1b study combining GTB-5550 with a KRAS inhibitor in pancreatic cancer patients.
